Study guide

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR

Key Takeaways Explain This Topic AI

The National Cancer Act of 1971 established the NCI Surveillance, Epidemiology, and End Results (SEER) program, currently covering approximately 48% of the United States population across geographically and demographically diverse registries.

Congress established the CDC National Program of Cancer Registries (NPCR) under the Cancer Registries Amendment Act of 1992 (Public Law 102-515) to fund and standardize central cancer registries across 46 states, DC, and US territories.

Together, SEER and NPCR achieve 100% population-based cancer surveillance coverage across the entire United States.

The United States Cancer Statistics (USCS) is the official federal cancer statistics report produced jointly by the CDC and NCI, operating under a standard 24-month reporting delay to allow complete case consolidation and quality auditing.

SEER emphasizes active longitudinal patient follow-up, specialized molecular and clinical substudies, and survival tracking, whereas NPCR prioritizes comprehensive state-level public health planning and cancer control interventions.

Last updated: September 2026

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR

Population-based cancer surveillance provides the objective empirical bedrock for cancer prevention, etiology research, healthcare resource allocation, and survivorship evaluation in the United States. Unlike hospital cancer registries—which capture cases diagnosed or treated within a single institution to optimize clinical care and hospital accreditation—central population-based cancer registries monitor all newly diagnosed malignancies occurring among residents of a designated geographic territory, regardless of where diagnosis or treatment occurs.

At the national level, United States cancer surveillance is anchored by two complementary federal initiatives: the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) and the National Program of Cancer Registries (NPCR) administered by the Centers for Disease Control and Prevention (CDC). Working in synchronized coordination with standard-setting bodies, these two surveillance pillars capture 100% of newly diagnosed cancers across the nation.

The NCI Surveillance, Epidemiology, and End Results (SEER) Program

The SEER program was established pursuant to the National Cancer Act of 1971 (Public Law 92-218), signed into law by President Richard Nixon, which launched the national "War on Cancer" and mandated the collection, analysis, and dissemination of cancer data in the United States. Operational data collection under SEER began on January 1, 1973, initially encompassing nine geographic registries.

Scope and Demographic Representation

Over the ensuing decades, the SEER program strategically expanded its geographic footprint to reflect the shifting demographic composition of the United States. Successive expansions—moving from SEER 9 to SEER 13, SEER 18, SEER 21, and subsequent expansion registries—were designed to intentionally oversample historically underrepresented racial, ethnic, and rural populations. Today, SEER registries cover approximately 48% of the United States population , including substantial representation of African American, Hispanic, American Indian/Alaska Native, Asian American, and Native Hawaiian/Pacific Islander communities.

The original SEER 9 registries (Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah and Atlanta) provide the longest trends. Later expansions added registries such as Los Angeles, San Jose-Monterey, rural Georgia and the Alaska Native Tumor Registry, then greater California, Kentucky, Louisiana, New Jersey and greater Georgia, and more recently additional states such as Idaho, New York, Massachusetts, Illinois and Texas. SEER's published groupings (SEER 8, 12, 17, 22 and so on) let analysts pick the longest trend or the broadest coverage.

Core Mission and Epidemiologic Focus

SEER functions as the premier biomedical research surveillance system in global oncology. Its core missions encompass:

Longitudinal Patient Follow-Up: SEER registries maintain active patient follow-up systems to track vital status, cause of death, and long-term relative survival rates spanning decades.

Specialized Biospecimen and Clinical Registries: SEER operates specialized programs such as the Residual Tissue Repository (RTR) , which links annotated tumor tissue biospecimens with curated registry clinical data.

Rapid Response Surveillance Studies (RRSS): An agile infrastructure allowing researchers to conduct targeted patient contact, genetic subtyping studies, and quality-of-life surveys within months of initial diagnosis.

SEER*Stat Analytical Software: The NCI develops and distributes the standard analytical software suite used worldwide by epidemiologists to calculate incidence, mortality, relative survival, and prevalence statistics.

The CDC National Program of Cancer Registries (NPCR)

Despite the scientific excellence of SEER, by the early 1990s significant cancer surveillance deficits persisted across large swaths of the United States. Many states lacked central cancer registries entirely, operated under inadequate state legislative authorities, or suffered from chronic underfunding that precluded complete statewide case ascertainment. In response, Congress enacted the Cancer Registries Amendment Act of 1992 (Public Law 102-515), establishing the National Program of Cancer Registries (NPCR) under the administrative authority of the CDC Division of Cancer Prevention and Control (DCPC).

Legislative Mandates and Scope

The Cancer Registries Amendment Act authorized the CDC to provide direct financial grants and technical assistance to states and territories to establish and enhance central cancer registries. To qualify for federal NPCR funding, states were mandated to enact state-level legislation establishing:

Mandatory reporting of cancer cases by hospitals, pathology laboratories, ambulatory surgical centers, radiation oncology clinics, and private physician practices.

Statutory protection from liability for healthcare providers submitting required cancer records to the central registry.

Unrestricted access for registry field abstractors to review medical records to verify complete case ascertainment.

Strict statutory protections guaranteeing patient and facility confidentiality.

Today, NPCR funds and oversees central registries in 46 states, the District of Columbia, Puerto Rico, the United States Virgin Islands, and the Pacific Island jurisdictions . Several states—such as California, Georgia, New York, and Kentucky—receive dual funding from both SEER and NPCR for designated portions of their population or analytical activities.

Public Health and Cancer Control Mission

Whereas SEER maintains a specialized biomedical research and survival orientation, the CDC NPCR is fundamentally oriented toward public health planning, community cancer control, and health equity :

Comprehensive Cancer Control (CCC): NPCR data serve as the direct empirical foundation for state Comprehensive Cancer Control Plans, guiding community breast and cervical cancer screening initiatives, colorectal screening expansions, and tobacco cessation programs.

Assessing Environmental and Occupational Clusters: NPCR central registries investigate potential community cancer clusters, assess geographic disease burden, and evaluate local environmental exposures.

Data Modernization and Electronic Pathology (e-Path): NPCR has spearheaded nationwide automated electronic reporting from commercial and hospital pathology laboratories using HL7 messaging standards.

Comparative Matrix: SEER vs. CDC NPCR

Understanding the operational, statutory, and functional distinctions between SEER and NPCR is essential for the Oncology Data Specialist examination:

Surveillance Dimension NCI SEER Program CDC NPCR

Founding Legislation National Cancer Act of 1971 (P.L. 92-218) Cancer Registries Amendment Act of 1992 (P.L. 102-515)

Lead Federal Agency National Cancer Institute (NCI / NIH) Centers for Disease Control and Prevention (CDC / HHS)

Population Coverage ~48% of the United States population Central registries in 46 states, DC, PR, VI, and Pacific territories

Primary Strategic Focus Etiology research, precision epidemiology, survival tracking, and clinical substudies Public health planning, state cancer control interventions, and screening outreach

Follow-Up Methodology Active Longitudinal Follow-Up: Continuous tracking of individual vital status, recurrence, and cause of death Passive Follow-Up: Primarily electronic data linkage with state vital statistics, the National Death Index (NDI), and CMS files

Analytical Software SEER Stat, SEER Prep, SEER*Abs SEER*Stat (collaborative integration) and CDC WONDER

Data Sharing Products SEER Research Data Files (public-use microdata) NPCR Cancer Surveillance System (NPCR-CSS) data submissions

Combined National Coverage & United States Cancer Statistics (USCS)

Prior to the late 1990s, the United States lacked a single, unified national publication reporting cancer incidence across the entire country. The synthesis of SEER and NPCR eliminated this historic divide. Together, SEER and NPCR capture 100% of newly diagnosed cancers across all 50 states and territories . ┌────────────────────────────────────────────────────────────────────────┐

  • │ 100% US Population Coverage │
  • │ │
  • │ ┌──────────────────────────────┐ ┌────────────────────────────┐ │
  • │ │ NCI SEER (~48%) │ │ CDC NPCR (46 States, │ │
  • │ │ Survival & Molecular Focus │ │ DC & Territories) │ │
  • │ └──────────────┬───────────────┘ └─────────────┬──────────────┘ │
  • │ │ │ │
  • │ └────────────────┬─────────────────┘ │
  • │ ▼ │
  • │ United States Cancer Statistics (USCS) │
  • │ Official Joint Federal Cancer Report │
  • └────────────────────────────────────────────────────────────────────────┘
  • The United States Cancer Statistics (USCS) Report

In 2002, the CDC and NCI published the first joint edition of United States Cancer Statistics (USCS) . Published annually, USCS is the official federal report on cancer incidence and mortality. It combines registry data from both NPCR and SEER, alongside mortality data from the CDC National Center for Health Statistics (NCHS).

The 24-Month Reporting Delay Standard

A hallmark of national cancer surveillance is the standard 24-month reporting lag . For example, official cancer incidence data for diagnosis year 2024 are released in late 2026 or early 2027. This deliberate two-year interval is required to ensure:

Complete case ascertainment across outpatient, ambulatory surgery, and pathology venues.

In-depth central registry consolidation, deduplication, and cross-facility case linkage.

Death certificate clearance and linkage with state vital statistics.

Multi-tiered data quality auditing against national NAACCR standards.

  • Practice Scenario & Exam Pitfalls
  • Clinical Practice Scenario

A state public health department is drafting a legislative grant to expand statewide colorectal cancer screening in high-risk rural counties. The health commissioner requests cancer incidence, stage at diagnosis, and demographic disparities for every rural county across the state.

Surveillance Application: Because this project requires comprehensive statewide coverage across all 67 counties—including non-SEER rural regions—the analyst queries the state's central registry operating under CDC NPCR funding. If the project instead sought five-decade longitudinal relative survival curves with curated biobank tumor block retrieval, the analyst would partner with an NCI SEER specialized repository registry.

Core Exam Pitfalls to Avoid

Pitfall 1: Assuming SEER covers the entire United States alone. SEER covers approximately 48% of the population via representative sampling. Complete 100% national coverage is achieved only through the combined data of SEER and NPCR.

Pitfall 2: Confusing statutory authorities. The National Cancer Act of 1971 created SEER; the Cancer Registries Amendment Act of 1992 created the CDC NPCR. The ODS-C exam frequently tests the legislation and founding year associated with each agency.

Pitfall 3: Misidentifying USCS governance. The United States Cancer Statistics report is not published by CDC alone or NCI alone; it is a collaborative joint federal report produced by both CDC and NCI in partnership with standard-setting organizations.

Loading diagram... United States National Cancer Surveillance System Architecture